



Know the FACTS

WHEN
weTri(al)



It is important you know the facts about how breast cancer impacts Black lives, so you can make the best decisions for your life.

Find additional facts about breast cancer at:

www.breastcancer.org | www.touchbbca.org

Black women are dying at disproportionate rates:

Though incidence rates are about the same, **Black women diagnosed with breast cancer die at a 41% higher rate** than white women.

Since 1990, breast cancer deaths have **decreased** by **40%** in white women, but by **only 26%** in Black women.

Racial differences in breast cancer diagnoses and deaths are largely driven by disparities seen in younger Black women:

Among women diagnosed with breast cancer younger than age 50, **Black women die at twice the rate** as white women in the same age group (1.9 – 2.6 times the mortality rate).

Black women under 30 are **38%** more likely to be diagnosed with breast cancer and **2.6 times** more likely to die of the disease than white women in the same age group.

Black patients are more likely to be diagnosed with more aggressive breast cancers at more advanced stages:

8% of Black breast cancer patients are diagnosed with **metastatic disease** compared to 5-6% of patients of other racial / ethnic groups.

Black women are more likely to be **diagnosed with higher grade and larger** cancers.

Triple-negative breast cancers are more aggressive and difficult to treat than other breast cancer subtypes. **Black women are diagnosed with triple-negative breast cancer at twice the rate** as white women. About **21%** of breast cancers diagnosed in Black women are **triple negative**, compared with 10% in whites.

PRIMARY SOURCES OF DATA IN THIS FACT SHEET INCLUDE:

- <https://acsjournals.onlinelibrary.wiley.com/doi/full/10.3322/caac.21708>
- <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/>

When We Tri(al) is a movement driven by #BlackDataMatters. #BlackDataMatters: Black Breast Cancer and Barriers to Clinical Trial Research is supported by a grant from Genentech, a member of the Roche Group, and sponsored by AstraZeneca and Bristol Myers Squibb.